ImmunityBio
IBRX
9.75
+0.06
+0.62%
ImmunityBio
US · IBRX
#1397 by market cap
Listed 1970
9.75
+0.06
+0.62%
Live - 5344 symbols - heartbeat 403s ago
· 2026-10-08 08:16
Pre-market
9.69
-0.62%
After-hours
9.77
+0.16%
Overnight
9.70
-0.51%
- Market cap
- 10.33B
- P/E (TTM)i
- -10.26
- P/Bi
- -9.87
- EPSi
- -0.38
- Div yieldi
- 0.00%
- 52W posi
- 74%
Reader sentiment
Are you bullish or bearish on IBRX?
Anonymous reader poll. Unscientific, not investment advice.
Analyst consensus 3 analysts
Buy
Avg price target
13.00 +33.3%
Price target rangecurrent 9.75
Low12.00
Avg13.00
High15.00
Buy 100%
Hold 0%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-09-08 | Piper Sandler | -- | BUY | 12.00 |
| 2026-08-04 | BTIG | -- | BUY | 12.00 |
| 2026-08-04 | H.C. Wainwright | -- | BUY | 15.00 |
| 2026-06-02 | H.C. Wainwright | -- | BUY | 15.00 |
| 2026-06-01 | Piper Sandler | -- | BUY | 12.00 |
| 2026-05-18 | H.C. Wainwright | -- | BUY | 15.00 |
| 2026-05-08 | Piper Sandler | -- | BUY | 12.00 |
| 2026-05-08 | BTIG | -- | BUY | 12.00 |
| 2026-05-08 | H.C. Wainwright | -- | BUY | 15.00 |
| 2026-04-29 | H.C. Wainwright | -- | BUY | 15.00 |
| 2026-04-09 | H.C. Wainwright | -- | BUY | 15.00 |
| 2026-03-24 | BTIG | -- | BUY | 13.00 |
| 2026-03-17 | BTIG | -- | BUY | 13.00 |
| 2026-03-17 | H.C. Wainwright | -- | BUY | 15.00 |
| 2026-03-12 | BTIG | -- | BUY | 13.00 |
| 2026-03-11 | BTIG | -- | BUY | 13.00 |
| 2026-03-04 | Piper Sandler | -- | BUY | 12.00 |
| 2026-03-04 | H.C. Wainwright | -- | BUY | 15.00 |
| 2026-02-23 | H.C. Wainwright | -- | BUY | 15.00 |
| 2026-02-18 | H.C. Wainwright | -- | BUY | 10.00 |
| 2026-01-26 | H.C. Wainwright | -- | BUY | 10.00 |
| 2026-01-20 | Piper Sandler | -- | BUY | 7.00 |
| 2026-01-20 | H.C. Wainwright | -- | BUY | 8.00 |
| 2026-01-14 | H.C. Wainwright | -- | BUY | 8.00 |
| 2025-12-15 | Piper Sandler | -- | BUY | 5.00 |
Quant vs Street three independent views, side by side
Momentum strategy signal
Buy
Analyst consensus
Buy
All 2 views agree: bullish.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
Price target trend monthly average, last 3 years
Quote time 2026-10-08 08:16:09 · For reference only, not investment advice and not tailored to your situation.